Medical Cannabis in the UK: Prescriptions, Products, Driving and Safer Use

Medical cannabis collection · Expanded 11 October 2026

Medical cannabis is legally available in the UK through defined prescribing routes, but legal availability, a product licence and NHS access are different things. Understanding those distinctions helps patients ask better questions and avoids the assumption that any cannabis product becomes a suitable medicine simply because someone uses it for a symptom.

Medical and regulatory sources checked: 1 October 2026. This overview is not personal medical or legal advice. Prescribers, pharmacists and the relevant authorities should resolve individual circumstances.

“It’s illegal in England, Scotland and Wales to drive with legal drugs in your body if it impairs your driving.”

GOV.UK — Drugs and driving: the law

The specified drug-limit framework described by this source applies to Great Britain. Northern Ireland has a different framework; impaired driving remains an offence.

How prescribing became possible

The 2018 regulatory changes created a prescribing route for qualifying cannabis-based products for medicinal use. Initiation of unlicensed products is restricted to doctors on the General Medical Council’s Specialist Register. The change did not legalise recreational supply or home cultivation. The Home Office explanation describes the framework.

A clinic’s eligibility questionnaire is a screening tool, not a guarantee of a prescription. A medical assessment should establish the diagnosis, previous treatment, relevant risks and whether a particular product is justified. A rule such as “two treatments tried” should not be confused with a universal legal entitlement to cannabis.

Licensed and unlicensed products

A licensed medicine has a marketing authorisation for specified uses, backed by a regulatory assessment. Examples include purified CBD medicine for certain epilepsies and a THC/CBD spray for selected patients with MS spasticity. Nabilone, a synthetic cannabinoid medicine, can be used for persistent chemotherapy-related nausea and vomiting in appropriate circumstances. The NHS medical cannabis overview explains these uses and the restricted nature of NHS access.

Many privately prescribed cannabis oils and flower products are unlicensed medicines. “Unlicensed” does not mean automatically unlawful or devoid of quality controls. It does mean that the product does not have a marketing authorisation establishing the proposed use in the same way as a licensed medicine. The rationale, uncertainty and monitoring arrangements should be clear.

Similarly, legal private prescribing does not create an obligation for the NHS to fund or continue that treatment. Ask who will prescribe, who will review outcomes and what happens if the product becomes unavailable.

What a thorough assessment should cover

Bring a medication list and an accurate account of previous treatments, including why each was stopped. Relevant history includes mental health, substance use, heart disease, liver or kidney problems, pregnancy or breastfeeding, and previous reactions to cannabis. Discuss non-prescription CBD and alcohol as well as prescribed medicines. NICE NG144 sets out key prescribing considerations.

An assessment should also cover everyday responsibilities. Driving, operating equipment, caring for dependants and avoiding falls may influence whether a particular treatment is workable. A medicine can be biologically active yet poorly suited to a person’s circumstances.

Oils, capsules, mouth sprays and flower

The route changes how a medicine behaves. Health Canada’s route guidance describes faster onset with inhalation and slower, more prolonged effects after ingestion. Its pharmacology information is useful internationally; Canadian access rules should not be mistaken for UK law.

Smoking prescribed cannabis is prohibited under the relevant UK rules. A prescription does not authorise smoking. Vaporisation avoids combustion but is not risk-free; use only the medicine and route specified by the clinician. Do not improvise with unregulated liquids or additives.

Concentration is not a dosing plan

Milligrams, millilitres, percentages and grams describe different things. The total CBD in a bottle does not say how much is in a single dose. A THC:CBD ratio does not reveal the absolute quantity of either compound. The label, written directions and pharmacist’s explanation should agree.

Ask for clarification before making a conversion or substituting a new product. There is no universal dose suitable for every condition, preparation and patient. Treatment changes should be guided by benefit, adverse effects and the prescriber’s plan, rather than by a search for the highest available THC percentage.

Driving and work

It remains illegal to drive while impaired by a prescribed medicine. A statutory medical defence to a specified drug-limit offence does not provide a defence to impaired driving. The Department for Transport guidance explains this distinction.

Do not assume that feeling less intoxicated, possessing a prescription or waiting a fixed number of hours proves fitness to drive. Ask the prescriber about your formulation and other medicines. Occupational requirements may also matter, especially where alertness or rapid decisions are essential.

Travel, storage and other people

A UK prescription does not override another country’s drug laws. Before travelling, check the rules for the destination and transit countries, including documentation and any required permission. Government travel guidance recommends checking with the relevant embassy and carrying proof that controlled medicine was prescribed to you.

Keep medicine in its labelled packaging and store it securely away from children and anyone for whom it was not prescribed. Do not share it. Products that look like food require particular care because accidental ingestion can be serious. Health Canada’s safety information highlights poisoning and unwanted effects.

Follow-up is part of treatment

Agree the target symptom, a baseline, a review date and stopping criteria. Report troublesome sedation, dizziness, worsening anxiety or cognitive changes. CBD also needs medication review: the FDA describes interactions and liver-related concerns, even without THC intoxication.

Seek urgent help for serious reactions such as severe confusion, chest pain, collapse or persistent vomiting with dehydration. For routine review, bring a record of both benefit and harm. A valid prescription begins a monitored treatment relationship; it does not remove the need to establish that the medicine remains useful.

A checklist for the first follow-up

This turns follow-up into an assessment of a treatment rather than a renewal of a label. Keep the prescriber and regular healthcare team informed, particularly when care is divided between private and NHS services. A brief written record is easier to compare over time than a general impression formed on the best or worst day.